Showing results (371-380 of 413) with videos related to

Sort By:
Pageof 42
Medecine Tropicale : Revue Du Corps De Sante Colonial|January 5, 2007
[Malaria in the central highlands of Madagascar: control strategies]L P Rabarijaona, T Rabe, L H Ranaivo, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 26, 2017
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trialV Möbus, C Jackisch, H J Lück, et al.
British Journal of Cancer|September 16, 1999
Intron variants of the p53 gene are associated with increased risk for ovarian cancer but not in carriers of BRCA1 or BRCA2 germline mutationsS Wang-Gohrke, W Weikel, H Risch, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 12, 2010
Intense dose-dense sequential chemotherapy with epirubicin, paclitaxel, and cyclophosphamide compared with conventionally scheduled chemotherapy in high-risk primary breast cancer: mature results of an AGO phase III studyVolker Moebus, Christian Jackisch, Hans-Joachim Lueck, et al.
Tumour Virus Research|July 27, 2023
Association of two genomic variants with HPV type-specific risk of cervical cancerFinja Seifert, Rieke Eisenblätter, Julia Beckmann, et al.
International Journal of Surgery (London, England)|February 24, 2025
Risk factors for anastomotic leakage and its impact on survival outcomes in radical multivisceral surgery for advanced ovarian cancer: an AGO-OVAR.OP3/LION exploratory analysisFabian Trillsch, Bastian Czogalla, Sven Mahner, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 24, 2012
A randomized phase III adjuvant study in high-risk cervical cancer: simultaneous radiochemotherapy with cisplatin (S-RC) versus systemic paclitaxel and carboplatin followed by percutaneous radiation (PC-R): a NOGGO-AGO Intergroup StudyJ Sehouli, I B Runnebaum, C Fotopoulou, et al.
JCO Precision Oncology|January 30, 2023
Homologous Recombination Repair Gene Mutations to Predict Olaparib Plus Bevacizumab Efficacy in the First-Line Ovarian Cancer PAOLA-1/ENGOT-ov25 TrialEric Pujade-Lauraine, Jessica Brown, Alan Barnicle, et al.
Gynecologic Oncology|December 10, 2024
Palbociclib plus letrozole in estrogen receptor-positive advanced/recurrent endometrial cancer: Double-blind placebo-controlled randomized phase II ENGOT-EN3/PALEO trialMansoor R Mirza, Line Bjørge, Frederik Marmé, et al.
Pharmacogenetics|October 23, 2001
Progesterone receptor variant increases ovarian cancer risk in BRCA1 and BRCA2 mutation carriers who were never exposed to oral contraceptivesI B Runnebaum, S Wang-Gohrke, D Vesprini, et al.
Pageof 42